The role of P-glycoprotein in determining the oral absorption and clearance of the NK2 antagonist, UK-224,671
- 1 November 2000
- journal article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 12 (1) , 41-50
- https://doi.org/10.1016/s0928-0987(00)00144-5
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Pharmacokinetics and metabolism of a sulphamide NK2antagonist in rat, dog and humanXenobiotica, 2000
- Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug deliveryAdvanced Drug Delivery Reviews, 1997
- Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorptionAdvanced Drug Delivery Reviews, 1997
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 1997
- Physicochemical and drug-delivery considerations for oral drug bioavailabilityDrug Discovery Today, 1996
- Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans*Clinical Pharmacology & Therapeutics, 1996
- The Contribution of Intestinal Secretion to the Dose-Dependent Absorption of CeliprololPharmaceutical Research, 1994
- Dose-Dependent Intestinal Absorption and Significant Intestinal Excretion (Exsorption) of the β-Blocker Pafenolol in the RatPharmaceutical Research, 1993
- Epithelial Transport Of Drugs In Cell Culture. I: A Model For Studying The Passive Diffusion Of Drugs Over Intestinal Absorbtive (Caco-2) CellsJournal of Pharmaceutical Sciences, 1990
- Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoinJournal of Pharmacokinetics and Biopharmaceutics, 1980